WEBSITE BSE:538019 NSE: OBI LTD Inc. Year: 2005 Industry: Aquaculture
Last updated: 00:00
Oceanaa Biotek Industries Ltd is an Indian company engaged in the biotechnology and pharmaceutical sector, focusing on the research, development, and manufacturing of bio-based products and healthcare solutions. The company serves domestic and international markets, providing products for pharmaceuticals, agriculture, and industrial applications. Oceanaa Biotek Industries Ltd emphasizes innovation, quality, regulatory compliance, and operational efficiency while building its presence in the competitive biotechnology and life sciences industry.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹3 Cr.
Stock P/E 1.3
P/B 0.1
Current Price ₹2.4
Book Value ₹ 20.1
Face Value 10
52W High ₹0
Dividend Yield 0%
52W Low ₹ 0
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 14 | 8 | 3 | 5 | 5 | 3 | 13 | 5 | 4 | 1 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 14 | 8 | 3 | 5 | 5 | 3 | 13 | 5 | 4 | 1 |
| Total Expenditure | 11 | 7 | 27 | 3 | 3 | 2 | 13 | 3 | 3 | 2 |
| Operating Profit | 3 | 1 | -24 | 2 | 2 | 1 | -0 | 2 | 1 | -1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 2 | 0 | -24 | 1 | 1 | 1 | -1 | 1 | 0 | -1 |
| Provision for Tax | 1 | 0 | 0 | -0 | 0 | -0 | 0 | 0 | 0 | -0 |
| Profit After Tax | 2 | 0 | -24 | 1 | 1 | 1 | -1 | 1 | 0 | -1 |
| Adjustments | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 2 | 0 | -24 | 1 | 1 | 1 | -1 | 1 | 0 | -1 |
| Adjusted Earnings Per Share | 1.2 | 0.1 | -17.5 | 0.9 | 1 | 0.8 | -1 | 0.9 | 0.1 | -1.1 |
| #(Fig in Cr.) | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 0 | 0 | 0 | 7 | 46 | 32 | 36 | 60 | 36 | 26 | 23 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 0 | 0 | 0 | 7 | 46 | 32 | 36 | 61 | 36 | 26 | 23 |
| Total Expenditure | 0 | 0 | 0 | 6 | 44 | 27 | 31 | 39 | 54 | 21 | 21 |
| Operating Profit | -0 | -0 | 0 | 1 | 2 | 5 | 5 | 21 | -18 | 5 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 3 | 2 | 1 |
| Exceptional Income / Expenses | 0 | 0 | 0 | -0 | -0 | -0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -0 | -0 | 0 | 1 | 1 | 4 | 4 | 17 | -21 | 2 | -1 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 6 | -1 | 0 | 0 |
| Profit After Tax | -0 | -0 | 0 | 0 | 1 | 2 | 3 | 11 | -20 | 2 | -1 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -0 | -0 | 0 | 0 | 1 | 2 | 3 | 11 | -20 | 2 | -1 |
| Adjusted Earnings Per Share | -12.4 | -8.4 | 0.1 | 0.4 | 0.8 | 2.1 | 2.7 | 8.1 | -14.8 | 1.6 | -1.1 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -28% | -10% | -11% | 0% |
| Operating Profit CAGR | 0% | 0% | 20% | 0% |
| PAT CAGR | 0% | -13% | 15% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 0% | 0% | -22% | -14% |
| ROE Average | 8% | -4% | 6% | 5% |
| ROCE Average | 10% | 4% | 15% | 11% |
| #(Fig in Cr.) | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | -0 | -0 | 3 | 6 | 10 | 12 | 15 | 45 | 25 | 27 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Other Non-Current Liabilities | 0 | 0 | 0 | -0 | 0 | -0 | 0 | 1 | 0 | 0 |
| Total Current Liabilities | 0 | 0 | 0 | 4 | 3 | 7 | 7 | 13 | 13 | 12 |
| Total Liabilities | 0 | 0 | 3 | 10 | 13 | 19 | 22 | 60 | 39 | 41 |
| Fixed Assets | 0 | 0 | 0 | 0 | 7 | 7 | 6 | 24 | 17 | 21 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 0 | 0 | 3 | 10 | 6 | 13 | 17 | 36 | 23 | 20 |
| Total Assets | 0 | 0 | 3 | 10 | 13 | 19 | 22 | 60 | 39 | 41 |
| #(Fig in Cr.) | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow from Operating Activities | 0 | 0 | 0 | -0 | 2 | 1 | 1 | 2 | -5 | 7 |
| Cash Flow from Investing Activities | 0 | 0 | 0 | 0 | -8 | -1 | -0 | -22 | 5 | -6 |
| Cash Flow from Financing Activities | 0 | 0 | 0 | 2 | 4 | -0 | -0 | 20 | -0 | -0 |
| Net Cash Inflow / Outflow | 0 | 0 | 0 | 2 | -2 | 0 | -0 | 0 | -0 | 0 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -12.45 | -8.44 | 0.05 | 0.39 | 0.79 | 2.13 | 2.7 | 8.06 | -14.78 | 1.63 |
| CEPS(Rs) | -12.45 | -8.44 | 0.05 | 0.4 | 1.4 | 3.45 | 3.78 | 10.62 | -12.94 | 3.23 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0.35 | 0.6 | 1.5 | 0 | 0 |
| Book NAV/Share(Rs) | -49.51 | -45.11 | 5.77 | 6.21 | 10.02 | 11.73 | 14.8 | 33.35 | 18.62 | 20.26 |
| Core EBITDA Margin(%) | 0 | -111.59 | 12.19 | 11.16 | 4.54 | 15.98 | 14.7 | 34.77 | -49.33 | 18.45 |
| EBIT Margin(%) | 0 | -111.59 | 12.19 | 8.68 | 2.85 | 11.35 | 11.8 | 29.16 | -56.22 | 10.11 |
| Pre Tax Margin(%) | 0 | -116.66 | 12.18 | 8.59 | 2.73 | 11 | 11.71 | 27.97 | -56.68 | 9.71 |
| PAT Margin (%) | 0 | -143.53 | 8.36 | 5.19 | 1.74 | 6.78 | 7.49 | 18.09 | -55.27 | 8.64 |
| Cash Profit Margin (%) | 0 | -143.53 | 8.36 | 5.3 | 3.08 | 10.95 | 10.5 | 23.82 | -48.37 | 17.07 |
| ROA(%) | -63.4 | -96.04 | 1.71 | 5.35 | 6.98 | 13.28 | 13.19 | 26.44 | -40.26 | 5.53 |
| ROE(%) | 0 | 0 | 1.91 | 8.12 | 10.25 | 19.62 | 20.32 | 36.25 | -56.88 | 8.41 |
| ROCE(%) | 0 | 0 | 2.76 | 13.58 | 16.7 | 32.59 | 31.89 | 57.2 | -56.03 | 9.52 |
| Receivable days | 0 | 0 | 6.16 | 114.98 | 36.54 | 43.33 | 36.82 | 47.33 | 107.81 | 112.91 |
| Inventory Days | 0 | 0 | 184.11 | 0 | 0 | 53.68 | 47.93 | 34.2 | 35.01 | 9.19 |
| Payable days | 0 | 0 | 67.93 | 132.29 | 28.02 | 74.62 | 81.13 | 48.75 | 41.72 | 127.72 |
| PER(x) | 0 | 0 | 0 | 0 | 7.51 | 5.38 | 18.55 | 18.85 | 0 | 3.86 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0.59 | 0.98 | 3.38 | 4.56 | 1.3 | 0.31 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 3.07 | 1.2 | 0.99 | 0 | 0 |
| EV/Net Sales(x) | 0 | 0.45 | 8.83 | 0.46 | 0.13 | 0.35 | 1.39 | 3.42 | 0.93 | 0.36 |
| EV/Core EBITDA(x) | -0.42 | -0.4 | 72.45 | 4.12 | 2.9 | 2.22 | 9.32 | 9.81 | -1.89 | 1.92 |
| Net Sales Growth(%) | 0 | 0 | 3300 | 1872.31 | 592.64 | -30.82 | 13.43 | 65.83 | -39.98 | -29.29 |
| EBIT Growth(%) | -4131.82 | 47.26 | 471.54 | 1304.33 | 127.26 | 175.64 | 18.78 | 306.96 | -215.7 | 112.73 |
| PAT Growth(%) | 0 | 32.18 | 298 | 1124.48 | 131.8 | 169.92 | 26.3 | 297.73 | -283.36 | 111.06 |
| EPS Growth(%) | 0 | 32.18 | 100.64 | 631.24 | 101.59 | 169.92 | 26.3 | 199.06 | -283.36 | 111.06 |
| Debt/Equity(x) | 0 | 0 | 0 | 0 | 0.01 | 0.01 | 0 | 0.03 | 0.04 | 0.03 |
| Current Ratio(x) | 0.01 | 0.11 | 12.86 | 2.31 | 1.88 | 1.68 | 2.33 | 2.75 | 1.75 | 1.6 |
| Quick Ratio(x) | 0.01 | 0.11 | 12.19 | 2.31 | 1.88 | 1.05 | 1.64 | 2.26 | 1.71 | 1.54 |
| Interest Cover(x) | -3778.41 | -22.04 | 743.02 | 96.19 | 23.44 | 32.07 | 121.65 | 24.52 | -121.91 | 25.05 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0.02 | 0.01 | 0 | 0.01 | 0.03 | 0.09 |
| # | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 39.07 | 39.07 | 39.07 | 39.07 | 39.07 | 39.09 | 39.09 | 39.09 | 39.09 | 39.09 |
| FII | 0.02 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0.03 | 0 | 0 | 0 | 0 |
| Public | 60.91 | 60.93 | 60.93 | 60.93 | 60.93 | 60.88 | 60.91 | 60.91 | 60.91 | 60.91 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.83 | 0.83 | 0.83 | 0.83 | 0.83 | 0.83 | 0.83 | 0.83 | 0.83 | 0.83 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
